Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14962472 | 0.68 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL23927701 | 0.68 | GSR (0.31) | ALDH1A1 | |
| SCHEMBL23927677 | 0.68 | GSR (0.31) | ALDH1A1 | |
| SCHEMBL23927675 | 0.68 | GSR (0.31) | ALDH1A1 | |
| SCHEMBL2593997 | 0.67 | CYP2C19 (0.33) | CYP2C19ALDH1A1 | |
| SCHEMBL23927591 | 0.67 | PLG (0.47) | CYP2C19ALDH1A1 | |
| SCHEMBL23927593 | 0.67 | PLG (0.47) | CYP2C19ALDH1A1 | |
| SCHEMBL23927604 | 0.66 | CYP2C19 (0.55) | CYP2C19APLNRALDH1A1KDM4ECYP1A2 | |
| SCHEMBL9803653 | 0.66 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL23539178 | 0.65 | CYP2C19 (0.43) | CYP2C19APLNRALDH1A1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | VIVAVISION (SHANGHAI) LTD (CN) | 2022-10-20 | — | — | US | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | ROCK1, NOS1, ROCK2 | CYP2C19 678/4885APLNR 4744/4885ALDH1A1 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.